|
Gene: TTF2 |
Gene summary for TTF2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TTF2 | Gene ID | 8458 |
Gene name | transcription termination factor 2 | |
Gene Alias | F2 | |
Cytomap | 1p13.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R0F1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8458 | TTF2 | LZE4T | Human | Esophagus | ESCC | 6.09e-06 | 2.21e-01 | 0.0811 |
8458 | TTF2 | LZE24T | Human | Esophagus | ESCC | 4.25e-04 | 1.29e-01 | 0.0596 |
8458 | TTF2 | P1T-E | Human | Esophagus | ESCC | 2.84e-05 | 3.10e-01 | 0.0875 |
8458 | TTF2 | P2T-E | Human | Esophagus | ESCC | 7.70e-23 | 5.17e-01 | 0.1177 |
8458 | TTF2 | P4T-E | Human | Esophagus | ESCC | 3.78e-14 | 2.64e-01 | 0.1323 |
8458 | TTF2 | P5T-E | Human | Esophagus | ESCC | 1.84e-16 | 3.16e-01 | 0.1327 |
8458 | TTF2 | P8T-E | Human | Esophagus | ESCC | 9.19e-09 | 1.80e-01 | 0.0889 |
8458 | TTF2 | P10T-E | Human | Esophagus | ESCC | 7.27e-11 | 2.98e-01 | 0.116 |
8458 | TTF2 | P12T-E | Human | Esophagus | ESCC | 1.11e-08 | 1.52e-01 | 0.1122 |
8458 | TTF2 | P15T-E | Human | Esophagus | ESCC | 2.55e-03 | 1.02e-01 | 0.1149 |
8458 | TTF2 | P16T-E | Human | Esophagus | ESCC | 2.62e-04 | 1.08e-01 | 0.1153 |
8458 | TTF2 | P17T-E | Human | Esophagus | ESCC | 1.61e-07 | 3.52e-01 | 0.1278 |
8458 | TTF2 | P20T-E | Human | Esophagus | ESCC | 1.50e-08 | 2.35e-01 | 0.1124 |
8458 | TTF2 | P21T-E | Human | Esophagus | ESCC | 1.56e-19 | 4.47e-01 | 0.1617 |
8458 | TTF2 | P22T-E | Human | Esophagus | ESCC | 1.15e-05 | 1.15e-01 | 0.1236 |
8458 | TTF2 | P23T-E | Human | Esophagus | ESCC | 2.95e-13 | 4.04e-01 | 0.108 |
8458 | TTF2 | P24T-E | Human | Esophagus | ESCC | 2.80e-02 | 1.15e-01 | 0.1287 |
8458 | TTF2 | P26T-E | Human | Esophagus | ESCC | 2.36e-05 | 1.75e-01 | 0.1276 |
8458 | TTF2 | P27T-E | Human | Esophagus | ESCC | 3.21e-03 | 9.40e-02 | 0.1055 |
8458 | TTF2 | P28T-E | Human | Esophagus | ESCC | 1.57e-25 | 5.20e-01 | 0.1149 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:00063532 | Esophagus | ESCC | DNA-templated transcription, termination | 15/8552 | 21/18723 | 1.54e-02 | 4.96e-02 | 15 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTF2 | SNV | Missense_Mutation | c.490G>A | p.Asp164Asn | p.D164N | Q9UNY4 | protein_coding | tolerated(0.08) | benign(0.013) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
TTF2 | SNV | Missense_Mutation | c.1630N>A | p.Gly544Ser | p.G544S | Q9UNY4 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TTF2 | SNV | Missense_Mutation | c.980N>C | p.Gly327Ala | p.G327A | Q9UNY4 | protein_coding | tolerated(0.27) | benign(0.011) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTF2 | SNV | Missense_Mutation | novel | c.1928N>A | p.Gly643Glu | p.G643E | Q9UNY4 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTF2 | SNV | Missense_Mutation | c.828G>C | p.Gln276His | p.Q276H | Q9UNY4 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-AR-A24L-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | PD | |
TTF2 | SNV | Missense_Mutation | rs747157893 | c.1759N>A | p.Gln587Lys | p.Q587K | Q9UNY4 | protein_coding | deleterious(0) | possibly_damaging(0.908) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TTF2 | SNV | Missense_Mutation | rs765522575 | c.1527N>C | p.Lys509Asn | p.K509N | Q9UNY4 | protein_coding | tolerated(0.36) | benign(0) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TTF2 | insertion | Nonsense_Mutation | novel | c.60_61insATCTATTAAACATGTACAAATACATCATTTGCAAGAATAACAATCTTG | p.Arg20_Asp21insIleTyrTerThrCysThrAsnThrSerPheAlaArgIleThrIleLeu | p.R20_D21insIY*TCTNTSFARITIL | Q9UNY4 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
TTF2 | insertion | Frame_Shift_Ins | novel | c.38_39insCCCAAGATCATGCCACTGTACTCCAGCCTGGCAACAGAGCGAGACT | p.Phe14ProfsTer18 | p.F14Pfs*18 | Q9UNY4 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
TTF2 | insertion | Nonsense_Mutation | novel | c.1091_1092insAGACTGGAGGCACACACAAAAGAGACTTTTCTGAAA | p.Ser364_Lys365insAspTrpArgHisThrGlnLysArgLeuPheTerAsn | p.S364_K365insDWRHTQKRLF*N | Q9UNY4 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |